KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Change in Acquisitions & Divestments (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Change in Acquisitions & Divestments for 18 consecutive years, with $2.6 billion as the latest value for Q1 2026.

  • For Q1 2026, Change in Acquisitions & Divestments fell 24.63% year-over-year to $2.6 billion; the TTM value through Mar 2026 reached $10.7 billion, down 25.49%, while the annual FY2025 figure was $11.5 billion, 23.17% down from the prior year.
  • Change in Acquisitions & Divestments hit $2.6 billion in Q1 2026 for Regeneron Pharmaceuticals, up from $2.6 billion in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $4.3 billion in Q3 2024 and bottomed at $746.3 million in Q1 2022.
  • Average Change in Acquisitions & Divestments over 5 years is $2.6 billion, with a median of $2.6 billion recorded in 2025.
  • Year-over-year, Change in Acquisitions & Divestments surged 383.46% in 2022 and then tumbled 46.53% in 2025.
  • Regeneron Pharmaceuticals' Change in Acquisitions & Divestments stood at $1.5 billion in 2022, then soared by 55.0% to $2.4 billion in 2023, then increased by 8.36% to $2.6 billion in 2024, then decreased by 1.05% to $2.6 billion in 2025, then rose by 2.02% to $2.6 billion in 2026.
  • According to Business Quant data, Change in Acquisitions & Divestments over the past three periods came in at $2.6 billion, $2.6 billion, and $3.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.